logo-loader

First Cobalt ends 2Q with working capital of $14.7M

Published: 08:37 30 Aug 2021 EDT

First Cobalt - First Cobalt Corp. ends its second quarter with cash of $11.5 million and working capital of $14.7 million
First Cobalt's mission is to be the most sustainable producer of battery materials

First Cobalt (TSX-V:FCC, OTCQX:FTSSF) Corp. ended its second quarter with cash of $11.5 million and working capital of $14.7 million. 

In a statement, the company also said it remains on schedule to commission its expanded refinery in the 4Q of 2022, at which time it will become the only refiner of battery-grade cobalt sulfate in North America and the second-largest outside of China. 

READ: First Cobalt launches financing earmarked for construction of North American battery materials refinery

Other highlights for the quarter ended June 30, 2021 include:

  • Announced a US$45 million financing package comprising US$37.5 million of 6.95% senior secured convertible notes due December 1, 2026 and around US$7.5 million of common share equity offering. The financing package is subject to customary closing conditions and is expected to close on September 1, 2021;
  • Glencore loan converted to common shares of First Cobalt (TSX-V:FCC, OTCQX:FTSSF) on April 7, 2021;
  • Acquisition of the West Fork Property in Idaho to the west of the existing Iron Creek cobalt-copper deposit to expand the company's land position; 
  • Earn-in agreement on the Redcastle property located to the east of Iron Creek;
  • Launched an at-the-market equity program (ATM Program) in February 2021 for the issuance of up to $10 million of common shares from the treasury; 
  • Issued a total of 1,588,500 common shares under the ATM Program at an average price of $0.3436 per share, providing gross proceeds of $529,396; and 
  • In July 2021, a further 435,000 common shares were issued under the ATM Program at an average price of $0.3230 per share, providing gross proceeds of $140,505.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 35 minutes ago